These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 6788140)

  • 1. Postmarketing surveillance of adverse drug reactions in general practice. II: Prescription-event monitoring at the University of Southampton.
    Inman WH
    Br Med J (Clin Res Ed); 1981 Apr; 282(6271):1216-7. PubMed ID: 6788140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prescription-event monitoring. A preliminary study of benoxaprofen and fenbufen.
    Inman WH
    Acta Med Scand Suppl; 1984; 683():119-26. PubMed ID: 6234753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postmarketing surveillance of adverse drug reactions in general practice. I: search for new methods.
    Inman WH
    Br Med J (Clin Res Ed); 1981 Apr; 282(6270):1131-2. PubMed ID: 6786470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prescription-event monitoring: methodology and recent progress.
    Rawson NS; Pearce GL; Inman WH
    J Clin Epidemiol; 1990; 43(5):509-22. PubMed ID: 2324790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Terminology in prescription-event monitoring.
    Kubota K; Inman WH
    Eur J Clin Pharmacol; 1994; 46(6):497-500. PubMed ID: 7995314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of a postal survey of the reasons for non-response by doctors in a Prescription Event Monitoring study of drug safety.
    Key C; Layton D; Shakir SA
    Pharmacoepidemiol Drug Saf; 2002 Mar; 11(2):143-8. PubMed ID: 11998539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: analysis of 48 cohort studies.
    Martin RM; Biswas PN; Freemantle SN; Pearce GL; Mann RD
    Br J Clin Pharmacol; 1998 Nov; 46(5):505-11. PubMed ID: 9833605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A modified prescription-event monitoring study to assess the introduction of Seretide Evohaler in England: an example of studying risk monitoring in pharmacovigilance.
    Perrio MJ; Wilton LV; Shakir SA
    Drug Saf; 2007; 30(8):681-95. PubMed ID: 17696581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unlicensed and off label prescribing of drugs in general practice.
    McIntyre J; Conroy S; Avery A; Corns H; Choonara I
    Arch Dis Child; 2000 Dec; 83(6):498-501. PubMed ID: 11087285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of zafirlukast: results of a postmarketing surveillance study on 7976 patients in England.
    Twaites BR; Wilton LV; Shakir SA
    Drug Saf; 2007; 30(5):419-29. PubMed ID: 17472420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data.
    Layton D; Hughes K; Harris S; Shakir SA
    Rheumatology (Oxford); 2003 Nov; 42(11):1354-64. PubMed ID: 12867585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Informing the hospital of patients' drug regimens.
    Claoué C; Elkington AR
    Br Med J (Clin Res Ed); 1986 Jan; 292(6513):101. PubMed ID: 3080075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety profile of celecoxib as used in general practice in England: results of a prescription-event monitoring study.
    Layton D; Wilton LV; Shakir SA
    Eur J Clin Pharmacol; 2004 Sep; 60(7):489-501. PubMed ID: 15278327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety profile of orlistat: results of a prescription-event monitoring study.
    Acharya NV; Wilton LV; Shakir SA
    Int J Obes (Lond); 2006 Nov; 30(11):1645-52. PubMed ID: 16552401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the incidence rates of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data.
    Layton D; Heeley E; Hughes K; Shakir SA
    Rheumatology (Oxford); 2003 Nov; 42(11):1342-53. PubMed ID: 12832706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled Substance Prescribing Patterns--Prescription Behavior Surveillance System, Eight States, 2013.
    Paulozzi LJ; Strickler GK; Kreiner PW; Koris CM;
    MMWR Surveill Summ; 2015 Oct; 64(9):1-14. PubMed ID: 26469747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in 2000.
    Boshier A; Wilton LV; Shakir SA
    Eur J Clin Pharmacol; 2003 Dec; 59(10):767-73. PubMed ID: 14615857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. INFLUENCE OF DIFFERENT SOURCES OF THERAPEUTIC INFORMATION ON PRESCRIBING BY GENERAL PRACTITIONERS.
    WILSON CW; BANKS JA; MAPES RE; KORTE SM
    Br Med J; 1963 Sep; 2(5357):599-604. PubMed ID: 14049985
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data.
    Layton D; Hughes K; Harris S; Shakir SA
    Rheumatology (Oxford); 2003 Nov; 42(11):1332-41. PubMed ID: 12810929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-marketing studies: the work of the Drug Safety Research Unit.
    Mackay FJ
    Drug Saf; 1998 Nov; 19(5):343-53. PubMed ID: 9825948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.